Guardian Pharmacy Services, Inc. (GRDN)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $3.14B
Last updated: Nov 17, 2026 at 11:06 AM ET
Guardian Pharmacy Services, Inc. (GRDN) P/E Ratio & Valuation Multiples
Guardian Pharmacy Services (GRDN) trades at 41.2x trailing earnings and 2.1x sales. Its forward P/E is 33.2x. The median P/E across 11 similar companies is 25.3x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 24.1% higher over the next year. Its free cash flow yield is 2.9%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 41.2x |
| Forward P/E | 33.2x |
| Price to sales | 2.1x |
| Price to book | 11.7x |
| EV/EBITDA | 23.3x |
| Price to FCF | 34.3x |
|---|---|
| EV/FCF | 33.0x |
| PEG | N/A |
| FCF yield | 2.9% |
As of Nov 17, 2026
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GRDN
What is GRDN's forward P/E ratio?
Guardian Pharmacy Services has a forward P/E ratio of 33.2x.
Is GRDN stock overvalued?
GNG's valuation label for GRDN is Fairly valued. Its P/E of 41.2x compares with a median of 25.3x across 11 similar companies.
What is GRDN's price to sales ratio?
Guardian Pharmacy Services has a price to sales ratio of 2.1x.
GRDN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors